New horizons of methotrexate application

Methotrexate is an anti-inflammatory and anticancer drug that has been used in the treatment of various oncological and inflammatory diseases (such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, sarcoidosis, etc.). Scientists are working on finding optimal formulation that will maintain its efficacy and improve safety and nanoparticles have shown to be carriers with great potential as they protect the drug from degradation while at the same time they increase absorption. In vivo and in vitro studies of numerous nanoparticle preparations have showed that they generally have appropriate characteristics and can be carriers for targeted delivery of methotrexate to the tissues affected by disease. Topical preparations of methotrexate, mainly for the treatment of psoriasis, have also been assessed in various research and have showed promising results. Further research is warranted by the obtained results and will hopefully lead to new methotrexate formulations that will be approved by regulatory authorities and used instead of existing ones to improve efficacy of the drug and patients’ safety.

[1]  Yong-Bok Lee,et al.  Preparation and In Vitro/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery , 2019, International journal of molecular sciences.

[2]  H. Al‐Salami,et al.  Environmental Transformation of Pharmaceutical Formulations: A Scientific Review , 2019, Archives of Environmental Contamination and Toxicology.

[3]  Min-yan Wei,et al.  Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery , 2019, Pharmaceutics.

[4]  R. Löbenberg,et al.  Nanosized Liposomes Containing Bile Salt: A Vesicular Nanocarrier for Enhancing Oral Bioavailability of BCS Class III Drug. , 2017, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[5]  S. Youn,et al.  Methotrexate in a Real-World Psoriasis Treatment: Is It Really a Dangerous Medication for All? , 2017, Annals of dermatology.

[6]  S. Teimourian,et al.  An Overview of Inflammatory Bowel Disease: General Consideration and Genetic Screening Approach in Diagnosis of Early Onset Subsets , 2017, Middle East journal of digestive diseases.

[7]  M. Gremião,et al.  Bioadhesive Surfactant Systems for Methotrexate Skin Delivery , 2016, Molecules.

[8]  H. Herfarth,et al.  Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases , 2016, Inflammatory bowel diseases.

[9]  Meliha Ekinci,et al.  Methotrexate loaded chitosan nanoparticles: Preparation, radiolabeling and in vitro evaluation for breast cancer diagnosis , 2015 .

[10]  R. Neubert,et al.  Methotrexate for topical application in an extemporaneous preparation , 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[11]  Ahmed Abdelbary,et al.  Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. , 2015, International journal of pharmaceutics.

[12]  C. Nunes,et al.  A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. , 2014, International journal of pharmaceutics.

[13]  R. Giacomelli,et al.  Methotrexate: an old new drug in autoimmune disease , 2014, Expert review of clinical immunology.

[14]  H. Al‐Salami,et al.  Inflammatory bowel disease: clinical aspects and treatments , 2014, Journal of inflammation research.

[15]  B. Cronstein,et al.  Regulation of Inflammation by Adenosine , 2013, Front. Immunol..

[16]  S. Arora,et al.  Formulation and In Vitro Evaluation of Ufasomes for Dermal Administration of Methotrexate , 2012, ISRN pharmaceutics.

[17]  I. Tucker,et al.  Simultaneous determination of methotrexate and its polyglutamate metabolites in Caco-2 cells by liquid chromatography-tandem mass spectrometry. , 2009, Journal of pharmaceutical and biomedical analysis.

[18]  B. Cronstein,et al.  The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. , 2007, Arthritis and rheumatism.

[19]  E. Lower,et al.  A clinical approach to the use of methotrexate for sarcoidosis , 1999, Thorax.

[20]  B. Liagre,et al.  Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes. , 1998, The Journal of rheumatology.

[21]  M. Weinblatt,et al.  Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. , 1992, Arthritis and rheumatism.

[22]  M. Hicks,et al.  Ufasomes are Stable Particles surrounded by Unsaturated Fatty Acid Membranes , 1973, Nature.

[23]  H. Al‐Salami,et al.  Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants. , 2019, Technology and health care : official journal of the European Society for Engineering and Medicine.

[24]  Rana Jahanban-Esfahlan,et al.  New formulated "DOX-MTX-loaded nanoparticles" down- regulate HER2 gene expression and improve the clinical outcome in OSCCs model in rat: the effect of IV and oral modalities. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[25]  M. Weinblatt Methotrexate in rheumatoid arthritis: a quarter century of development. , 2013, Transactions of the American Clinical and Climatological Association.

[26]  J. Neradil,et al.  New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells. , 2012, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

[27]  I. Tucker,et al.  Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat. , 2009, The Journal of pharmacy and pharmacology.

[28]  M. Iannuzzi,et al.  The Diagnosis and Management of Sarcoidosis , 2006 .